Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag007 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Xiaojun Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. Hauptthemen laut MEDLINE: Granisetron, Palonosetron, Vomiting, Nausea. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
Chemotherapy-induced nausea and vomiting (CINV) significantly impact the patients’ quality of life. Whether the granisetron transdermal delivery system (GTDS) offers better protection than palonosetron against long-delayed (120-168 hours) CINV after highly or moderately emetogenic chemotherapy (HEC/MEC) had not been prospectively tested.
Methods
A multicenter, randomized clinical study was conducted in China. Patients scheduled to receive either HEC or MEC were randomly assigned (1:1) to GTDS or palonosetron, each in combination with a neurokinin-1 receptor antagonist (NK1-RA) and dexamethasone. The primary endpoint was the complete response (CR; no vomiting and no rescue medication) rate during the long-delayed phase (120-168 hours), stratified by HEC and MEC categories, to demonstrate the superiority of GTDS over palonosetron.
Results
Overall, 150 patients received either GTDS or palonosetron respectively. We found that the GTDS group demonstrated a significantly higher long-delayed CR rate (97.3%) than the palonosetron group (92%) (P = .04). This advantage was driven predominantly by the HEC subgroup (GTDS 97.5% vs palonosetron 90.8%, P = .028). No significant differences were observed between the groups for the acute (0-24 hours, 92.7% vs 90.0%; P = .412), delayed (24-120 hours, 80.0% vs 76.0%; P = .403), extended-delayed (24-168 hours, 80.7% vs 75.3%; P = .265), or overall (0-168 hours, 78.0% vs 74.0%; P = .417) phases.
Conclusion
A GTDS-based triple antiemetic regimen can effectively control CINV associated with HEC or MEC. It provides a convenient alternative route for delivering granisetron for up to 7 days, with superior efficacy in controlling long-delayed CINV.
Trial registration
Clinicaltrials.gov Identifier: NCT04912271 (in-house ethic number: YBCSG-21-04)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
- Minhang Branch, Fudan University Shanghai Cancer Center, Shanghai 201100, China.
- Department of Breast and Thyroid Surgery, Changhai Hospital, Naval Military Medical University, Shanghai 200433, China.
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.
ORCID-Profile: Xiaojun Liu, Xiaoxiang Guan, Jian Zhang
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Liu, X., Meng, Y., Du, Y., Mu, Y., Li, G., Li, H., Guan, X., & Zhang, J. (2026). Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial. The Oncologist. https://doi.org/10.1093/oncolo/oyag007
Vancouver
Liu X, Meng Y, Du Y, Mu Y, Li G, Li H, et al. Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial. The Oncologist. 2026. doi:10.1093/oncolo/oyag007
BibTeX
@article{Liu2026,
author = {Liu, Xiaojun and Meng, Yanchun and Du, Yiqun and Mu, Yuxin and Li, Gang and Li, Hengyu and Guan, Xiaoxiang and Zhang, Jian},
title = {Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag007}
}
EUVIMED